“Regulatory change is occurring like we haven’t seen since alcohol prohibition.”

Investment Highlights:

There is more public support for cannabis law reform than ever before with new polls showing more than half the country is in favor of legalizing cannabis. The Drug Policy Alliance believes cannabis should be removed from the criminal justice system and regulated like alcohol and tobacco.

Why should cannabis be legalized? First, to reduce harm. The criminalization of cannabis use disproportionately harms young people and people of color, sponsors massive levels of violence and corruption, and fails to curb youth access. Second, to create jobs. Legalizing and regulating cannabis will bring one of the nation's largest cash crops under the rule of law. This will create jobs and economic opportunities in the formal economy instead of the illicit market. Third, to save money. Scarce law enforcement resources will be better used to ensure public safety while reducing corrections and court costs. State and local governments would acquire significant new sources of tax revenue from regulating cannabis sales. Fourth, to promote consumer safety. Cannabis product testing is becoming a standard requirement for legalized cannabis markets. This means consumers are better informed about the cannabis they use.

Just how big is the market for legal cannabis? A recent report by a leading consulting firm found legal cannabis sales jumped 17% to $5.4 billion in 2015 and they will grow by a whopping 25% this year to reach $6.7 billion in total U.S. sales. More recently, another consulting firm prediction that the legal cannabis market will see a whopping $21.8 billion in total annual sales by 2020, which by comparison, at that point, the legal marijuana market could be bigger than the National Football League, which saw roughly $12 billion of revenue last year.

We are so excited for Focused Stock Trader to soon be providing you with investment research on the cannabis industry through our upcoming launch of In fact, our excitement is bubbling over so we are front running our upcoming launch with a quick review of 8 stocks. This is quite the opportune time for review considering legalizing medicinal use will be on the ballet in the United States across 23 states this year (25 already legal) and legalizing recreational use will be on the ballet in Canada next year (medicinal already legal at the federal level).


03/30/2017 Focused Stock Trader Team
Company Overview: 22nd Century is a plant biotechnology company focused on technology, which allows the company to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The company’s primary mission in tobacco is to reduce the harm caused by smoking. The company’s primary mission in cannabis is to develop proprietary cannabis strains for important new medicines and agricultural crops. 22nd Century currently owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications around the world.

MassRoots Inc. (MSRT): Softened Stance from Attorney General Regarding Cannabis a Positive Driver

03/17/2017 Focused Stock Trader Team
• MSRT shares lost 30% in recent weeks due to uncertainty in how the new administration in Washington will deal with the rapidly growing legalized cannabis industry in the U.S. • However, Attorney General Jeff Sessions took a much more pragmatic stance on the cannabis industry in the U.S. just yesterday • Expect shares of MSRT to rally in the coming days/weeks on yesterday’s clarification that erases much of the uncertainty that the market hates • MSRT shares are bouncing off the 200 day moving average of .78 and look prime for a breakout • MSRT is experiencing high sales growth and expects to be cash-flow positive in near term

Insys Therapeutics Inc. (NASDAQ: INSY)

02/24/2017 Focused Stock Trader
Company Description: Insys Therapeutics aims to take the rough edges off of chemo and cancer pain. The commercial-stage drug development company is focused on treating side effects of chemotherapy, as well as therapies for pain management. Its first product is Subsys, which brings in virtually all of its revenue; it is a fast-acting oral spray version of cancer pain drug Fentanyl. Syndros (dronabinol), which was approved by the FDA in mid-2016, is a generic liquid formulation of Marinol (a synthetic version of the active chemical in marijuana) for treatment of chemotherapy-induced nausea and vomiting. All of the company's drug candidates are re-formulations of already-approved therapeutic ingredients.

Kush Bottles (OTC: KSHB)

Introduction - Greetings and Happy New Year! This is the first article in our weekly series covering stocks in the burgeoning cannabis sector, one of the most rapidly growing and exciting of any industry in the publically-traded universe. Opportunities for both trading and investing profits will abound in 2017, but as with all stocks, there are inherent risks as we seek out these rewards. Our goal is to alert you to solid trades in the sector, and hopefully steer you away from some of the “weak sisters.” By way of background, I have been a stock trader for two decades, and have diligently tracked cannabis stocks on the OTC exchange for about ten of those years (yes, they’ve been out there that long). In addition to my FST work, I am currently serving as regional editor for Marijuana Industry News, a magazine published by MJIC media, a growing force in the cannabis investment industry.

MassRoots (OTCBB: MSRT)

MassRoots (OTCBB: MSRT) operates as a social network for the cannabis community. The Company operates a technology platform for the cannabis consumers, businesses and activists. The Company, through its mobile applications and Web platform, focuses on enabling users to share their cannabis content, follow their favorite dispensaries and stay connected with the legalization movement. Its technology platform consists of consumer-facing social network and its business-facing advertising portal, MassRoots for Business.


GW Pharmaceuticals is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies. The company operates through three segments: Commercial, Sativex Research and Development (Sativex R&D), and Pipeline Research and Development.


Zynerba Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis, and Fragile X syndrome.